1 / 19

Therapy of Inflammatory Bowel Diseases 2013

Gastroenterology Department Division of Medicine. Therapy of Inflammatory Bowel Diseases 2013. Eran Israeli MD. 100. 80. Penetrating. 60. % Cumulative Probability. 40. Inflammatory. Stricturing. 20. 0. 0. 12. 24. 36. 48. 60. 72. 84. 96. 108. 120. 132. 144. 156. 168. 180.

hanley
Download Presentation

Therapy of Inflammatory Bowel Diseases 2013

An Image/Link below is provided (as is) to download presentation Download Policy: Content on the Website is provided to you AS IS for your information and personal use and may not be sold / licensed / shared on other websites without getting consent from its author. Content is provided to you AS IS for your information and personal use only. Download presentation by click this link. While downloading, if for some reason you are not able to download a presentation, the publisher may have deleted the file from their server. During download, if you can't get a presentation, the file might be deleted by the publisher.

E N D

Presentation Transcript

  1. Gastroenterology DepartmentDivision of Medicine Therapy ofInflammatory Bowel Diseases2013 Eran Israeli MD

  2. 100 80 Penetrating 60 % Cumulative Probability 40 Inflammatory Stricturing 20 0 0 12 24 36 48 60 72 84 96 108 120 132 144 156 168 180 192 204 216 228 240 Months Patients at risk 95 2002 552 229 37 N = Long Term Evolution of Disease Behavior in CD Cosnes J et al. Inflamm Bowel Dis 2002;8:244-50.

  3. Goals of Treatment Remission Maintenance

  4. Goals of therapy • Induce and maintain remission • Ameliorate symptoms • Improve pts. quality of life • Adequate nutrition • Prevent complication of both the disease and medications • Mucosal healing

  5. Therapeutic Pyramidfor Active IBD Surgery Severe Immunomodulators Infliximab (Prednisone) ? Moderate Corticosteroids (Budesonide) Mild Aminosalicylates/Antibiotics

  6. 5-aminosalicylates • The mainstay treatment of mild to moderately active UC and CD (colitis). • 5-ASA may act by • blocking the production of prostaglandins and leukotrienes, • inhibiting bacterial peptide–induced neutrophil chemotaxis and adenosine-induced secretion, • scavenging reactive oxygen metabolites

  7. 5-aminosalycylates • Sulphasalazine first agent discovered • Group now includes: • Pentasa (mesalazine) • Asacol (mesalazine) • Rafassal (mesalazine) • Salazopyrin-EN (sulphasalazine) • Work locally on the lining of the gut to reduce inflammation

  8. Corticosteroids Enter cells and bind to and activate specific cytoplasmic receptors Steroid-receptor dimers enter cell nucleus activate steroid-responsive elements in DNA Gene repression or induction  anti-inflammatory effects Anti-inflammatory effects take several hours • Highly effective for the induction of remission in patients with active disease Short-term response rates (12–16 weeks) range from 70–90% • Not effective in maintenance of remission • Topical corticosteroids can be used as an alternative to 5-ASA in ulcerative proctitis or distal UC.

  9. Corticosteroids • IV -for patients who are sufficiently ill to require hospitalization; the majority will have a response within 7 to 10 days • Budesonide: • less side effects, • its use is limited to patients with distal ileal and right-sided colonic disease

  10. Corticosteroids -Acne -“Moon” face -Hair growth Cataract -“Buffalo” hump -Obesity -Purple / red streaks (striae) -Bruising -Bone thinning -Muscle weakness

  11. Immunomodulators • Inhibit ribonucleotide synthesis; • Induce T cell apoptosis • by modulating cell (Rac1) signalling • Metabolised to mercaptopurine • Drugs include: • Azathioprine • 6-mercaptopurine • Methotrexate • Interfere with inflammatory pathway • Effective- up to 75% of patients brought into remission • Slow- optimal effect often not seen until after 12 weeks of treatment • Need close monitoring for toxicity • Safety- Methotrexate not to be used in pregnancy

  12. Azathioprine Metabolism TPMT = thiopurine methyltransferase 6-TGN = 6-thioguanine nucleotide 6-MMPN = 6-methylmercaptopurine ribonucleotide

  13. TPMT • Tested before initiating therapy • Low TPMT activity related to high 6-TGN levels, increasing risk of toxicity • 6-TGN • Used to monitor therapy • Levels above 230 associated with better effect • Levels above 480 associated with more side effects

  14. Biological therapyanti-TNFa Infliximab Neutralisation of transmembrane TNF Neutralisation of soluble TNF TNF producing macrophages of activated T cells van Deventer SJH. Gut 1997: 40; 443–8. Scallon BJ et al. Cytokine 1995: 7; 251–9. Feldmann M et al. Adv Immunol 1997; 64: 283–350.

  15. Mouse Human PEG, polyethylene glycol. Construct of Anti-TNF-α Biologic Agents Certolizumab Pegol Infliximab Adalimumab VL VH CH1 No Fc PEG IgG1 IgG1 PEG Human recombinant antibody (100% humanIgG1 isotype) Chimeric monoclonal antibody (75% humanIgG1 isotype) Humanized Fab’fragment (95% humanIgG1 isotype)

  16. Anti-TNFa safety • Hypersensitivity • Allergic reaction at time of infusion – 5% • Autoimmune syndromes • Lupus like illness – rare and recovers on stopping on therapy • Infection • Profound immunosuppression occurs • Opportunistic infections can occur • Tuberculosis high risk • Hepatitis B can be reactivated • Cancer • Recent data suggests that overall cancer rates may be reduced • Hepatosplenic T-cell lymphomas – 1 in 20000 patients

  17. Integrins VCAM-1 MAdCAM-1 Integrin a4b7 Gut-homing T-cell Integrin a4b1

More Related